CJC-1295 vs Modified GRF (1-29): Why the Names Should Be Distinguished

CJC-1295 vs Modified GRF (1-29): Why the Names Should Be Distinguished

CJC-1295 and Modified GRF (1-29) should be distinguished because they are related but not structurally identical peptide materials. Modified GRF (1-29) generally refers to the tetrasubstituted 29-residue GHRH-related peptide backbone, whereas the compound originally described as CJC-1295 includes that modified backbone plus an additional C-terminal lysine carrying a reactive maleimide-containing group designed for albumin bioconjugation.

This distinction is central to CJC-1295 Research. When the names are merged, findings involving albumin-binding CJC-1295 can be attributed incorrectly to a shorter modified GRF peptide that lacks the same conjugated structure.

Research-use notice: InStrips products are offered for research and analytical use only. They are not intended to diagnose, treat, cure, or prevent any disease, injury, deficiency, absorption disorder, digestive condition, or medical condition.

The Two Names Share a Common Structural Background

Both terms are connected to research on the biologically active N-terminal region of human growth hormone-releasing factor.

The shared design lineage involves:

  • the GRF(1-29) sequence region
  • four amino-acid substitutions relative to native GRF(1-29)
  • GHRH-receptor-related pharmacology

The structural relationship explains why the names are often discussed together.

Shared Background Does Not Mean Identical Molecules

Two peptide materials can share most of a sequence while differing through one extension or conjugated group.

That difference can change:

  • molecular mass
  • chemical reactivity
  • protein association
  • pharmacokinetic behaviour
  • analytical detection

These differences are sufficient to require separate molecular terminology.

What Is Modified GRF (1-29)?

Modified GRF (1-29) is commonly used to describe a tetrasubstituted analog of the first 29 residues of human growth hormone-releasing factor.

The phrase communicates two pieces of information:

  • the peptide is derived from the GRF(1-29) region
  • the sequence has been modified relative to native GRF(1-29)

It does not, by itself, imply the albumin-binding extension found in the original CJC-1295 design.

What Does “Tetrasubstituted” Mean?

Tetrasubstituted means that four amino-acid positions have been changed relative to the reference GRF(1-29) sequence.

These substitutions are part of the synthetic analog's identity.

The term does not mean:

  • four peptides are combined
  • four receptors are targeted
  • four formulation components are present

The Modified GRF Backbone Is a 29-Residue Peptide

The GRF(1-29)-related backbone contains 29 amino-acid residues.

That sequence length distinguishes it from:

  • longer endogenous GHRH forms
  • CJC-1295 structures containing an additional C-terminal residue and conjugated group
  • other GHRH-related analogs

The Original CJC-1295 Structure Contains an Additional Residue

The FDA's current substance record for CJC-1295 defines a 30-residue peptide sequence rather than a 29-residue sequence.

The extra C-terminal lysine is chemically modified with a maleimide-containing group.

This added structural element is important because it distinguishes the defined CJC-1295 substance from the shorter modified GRF backbone.

The C-Terminal Lysine Is Not a Minor Naming Detail

Adding one residue changes the peptide sequence.

When that residue also carries a conjugated chemical group, the difference becomes even more significant.

Potentially affected analytical properties include:

  • molecular mass
  • chromatographic retention
  • charge characteristics
  • mass-spectrometric fragmentation
  • chemical reactivity

What Is the Maleimide-Containing Group?

The CJC-1295 design includes a maleimide-related reactive component attached through the C-terminal lysine.

Maleimide chemistry can react with thiol groups under appropriate conditions.

The research design used this chemistry to permit association with serum albumin.

Modified GRF (1-29) Does Not Contain the Same Albumin-Binding Extension

When Modified GRF (1-29) is used precisely to describe the non-DAC tetrasubstituted 29-residue peptide, it lacks the C-terminal albumin-binding structural component of the original CJC-1295 molecule.

This difference should be stated directly rather than hidden behind shorthand naming.

Why Albumin Association Matters for Research Classification

Albumin association can change how a peptide is investigated in circulation.

Researchers may need to distinguish:

  • free peptide
  • albumin-associated material
  • circulating persistence
  • sample preparation
  • pharmacokinetic profiles

A peptide without the reactive albumin-binding group does not represent the same molecular design.

Molecular Mass Should Differ

The 29-residue modified GRF backbone and the extended CJC-1295 structure have different expected molecular masses.

Mass analysis can therefore help distinguish:

  • the shorter backbone
  • the albumin-binding CJC-1295 form
  • truncated species
  • related impurities

Sequence Information Is More Reliable Than Catalogue Naming

A commercial or secondary source may use overlapping terminology.

A molecular specification provides stronger information by reporting:

  • complete amino-acid sequence
  • sequence length
  • terminal modifications
  • conjugated groups
  • molecular mass

Why “CJC-1295” Can Be Ambiguous Outside Primary Research

The original scientific literature anchors CJC-1295 to an albumin-binding molecular design.

Later commercial terminology has sometimes used CJC-1295 more broadly for:

  • DAC-associated material
  • non-DAC modified GRF material
  • products without complete structural information

This naming drift makes sequence verification important.

Why “Modified GRF (1-29)” Is More Structurally Informative for the Non-DAC Form

The term Modified GRF (1-29) directly states that the material is a modified analog of the first 29 residues of GRF.

It does not imply that a DAC-related albumin-binding structure is present.

For research writing, that makes the term more precise when the shorter tetrasubstituted peptide is actually being studied.

“Without DAC” Describes an Absence Rather Than a Complete Identity

The phrase “CJC-1295 without DAC” attempts to distinguish the shorter analog by specifying what is absent.

However, the phrase does not automatically tell a researcher:

  • the exact 29-residue sequence
  • which substitutions are present
  • the terminal form
  • salt or counterion form
  • analytical purity

Removing a Defining Modification Creates a Different Molecular Material

If a defining albumin-binding extension is removed from the original CJC-1295 structure, the resulting material is no longer chemically identical to that original structure.

This is why “same peptide but without DAC” can be misleading if interpreted too literally.

CJC-1295 and Modified GRF (1-29) Can Share Receptor Activity

Both belong to GHRH-receptor-related pharmacology.

Shared receptor activity can explain similarities in experimental receptor assays.

However, receptor activity does not establish molecular equivalence.

Receptor Agonism Is Not an Identity Test

A functional GHRH-receptor assay may respond to several related ligands.

Potential ligands can include:

  • native GHRH
  • GRF(1-29)
  • Modified GRF (1-29)
  • CJC-1295
  • other synthetic analogs

Molecular identification requires structural and analytical evidence.

Pharmacokinetic Findings Should Not Be Transferred Automatically

Albumin-binding CJC-1295 was specifically engineered and studied for prolonged circulating persistence.

A non-DAC 29-residue analog lacks that same structural feature.

Therefore, pharmacokinetic measurements from one should not automatically be assigned to the other.

Half-Life Is Compound Specific

A half-life value belongs to the exact compound, formulation, analytical method, and experimental system in which it was measured.

It should not be inherited from another related peptide merely because the names overlap.

Animal Findings Should Remain Compound Specific

Studies involving albumin-binding CJC-1295 in animals may examine:

  • circulating persistence
  • albumin association
  • growth hormone measurements
  • IGF-I-related measurements

Those findings should not automatically characterize non-DAC Modified GRF (1-29).

Human CJC-1295 Studies Used a Defined Investigational Compound

Published CJC-1295 human research was conducted using a defined investigational material associated with the albumin-binding development program.

A separately labelled non-DAC preparation should not be treated as though it participated in those same trials.

Clinical Literature Must Be Matched to the Molecular Form

When reviewing a human paper, researchers should determine:

  • the exact compound name
  • sequence or structural description
  • whether the albumin-binding modification was present
  • the investigational formulation

Cross-Form Evidence Can Otherwise Be Misattributed

If CJC-1295 DAC data are cited for Modified GRF (1-29), readers may incorrectly infer that the shorter peptide has the same:

  • pharmacokinetics
  • exposure profile
  • clinical evidence base
  • study history

Those conclusions require direct evidence.

The Same Problem Applies in Reverse

Research on Modified GRF (1-29) should not be used to redefine the molecular identity of CJC-1295 with its albumin-binding extension.

Salt Forms Create Another Layer of Terminology

A peptide can also be described as:

  • free base
  • acetate
  • trifluoroacetate
  • another counterion-associated form

These are additional molecular-form distinctions beyond the presence or absence of the DAC-associated structure.

FDA Review Illustrates the Naming Complexity

FDA materials reviewing CJC-1295-related bulk substances distinguish several separate categories, including CJC-1295 free base, CJC-1295 acetate, CJC-1295 DAC free base, CJC-1295 DAC acetate, and CJC-1295 DAC trifluoroacetate.

This illustrates why the broad name CJC-1295 does not always resolve the exact molecular form without additional specification.

FDA Substance Records Provide a Structural Anchor

The FDA Global Substance Registration System currently lists a defined CJC-1295 substance record containing a 30-residue sequence with a chemically modified C-terminal lysine.

This structural record provides a useful identity reference. It should not be interpreted as evidence that every commercial material labelled CJC-1295 contains that exact structure or meets a particular quality, regulatory, or clinical standard.

What Should a Research Article Report?

For a CJC-related peptide, a useful identity description may include:

  • 29- or 30-residue sequence
  • specific amino-acid substitutions
  • C-terminal modification
  • DAC-associated group present or absent
  • salt or counterion form
  • molecular mass
  • analytical method

Why This Matters for Literature Reviews

A literature table should separate studies according to the actual material used.

Useful categories include:

  • native GHRH
  • GRF(1-29)
  • Modified GRF (1-29)
  • CJC-1295 with albumin-binding modification
  • other GHRH analogs

Why These Names Should Not Become Comparative Claims

The structural distinction does not establish that one form is better, safer, more effective, or more desirable than another.

It establishes only that they are different molecular materials and should be evaluated separately.

Relationship to DAC Terminology

The albumin-binding structure associated with original CJC-1295 is commonly described using DAC terminology in later literature and commercial naming.

This terminology is examined in What Does “CJC-1295 With DAC” Mean in Research?.

Reading the Original CJC-1295 Molecular Paper

The PubMed-indexed paper Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog provides the primary molecular-development context for the compound originally named CJC-1295 and describes the added albumin-binding structural feature.

The paper is useful for molecular terminology and historical identification. Its experimental findings should not be transferred automatically to Modified GRF (1-29), separately labelled products, or personal-use contexts.

Final Perspective

CJC-1295 and Modified GRF (1-29) share a closely related GHRH-analog backbone but should not be treated as identical names.

Modified GRF (1-29) refers most clearly to the tetrasubstituted 29-residue peptide, whereas the original CJC-1295 design contains an additional C-terminal lysine with a maleimide-related albumin-binding group.

Accurate research coverage should preserve this structural distinction and should not transfer pharmacokinetic, clinical, safety, or other findings from one molecular form to the other without direct evidence.

Back to blog